Chemotherapy-Induced Cardiotoxicity

@article{Shaikh2012ChemotherapyInducedC,
  title={Chemotherapy-Induced Cardiotoxicity},
  author={Amir Y. Shaikh and J. Shih},
  journal={Current Heart Failure Reports},
  year={2012},
  volume={9},
  pages={117-127}
}
Anthracycline-based chemotherapeutics have long been recognized as effective agents for treating a wide range of malignancies. However, their use is not without significant adverse cardiotoxic side effects. Strategies for prevention involve limiting free-radical production and subsequent cardiac myocyte damage. Dexrazoxane remains the most widely studied cardioprotective medication. Alternative agents may reduce cardiotoxicity but may still cause significant cardiovascular problems. The role of… Expand
Chemotherapy-induced cardiotoxicity: detection, prevention, and management.
TLDR
The common systemic drugs with cardiotoxic potential and the monitoring and diagnostic tools, including the role of biomarkers for early detection, are reviewed and the use of cardioprotectant agents as pharmacological interventions in prophylactic and treatment settings is reviewed. Expand
Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy.
TLDR
A 52-year-old woman with cardiomyopathy following chemotherapy and radiation therapy is reported on, who did not respond well to b-blockers and angiotensin-converting enzyme inhibitors, and whose cardiac condition improved significantly after the addition of exogenous phosphocreatine. Expand
Cardiotoxicity associated with targeted cancer therapies (Review)
TLDR
These most commonly used drugs and associated incidence of cardiotoxicities, including left ventricular dysfunction, heart failure, hypertension and thromboembolic events are discussed and their respective molecular mechanisms of cardiovascular adverse effects are summarized. Expand
Duxorubicin-induced cardiotoxicity -
TLDR
Clinically, anthracycline induced cardiotoxicity manifests itself as left ventricular failure, which develops insidiously over months to years after completion of the anthrACYcline based chemotherapy and may result in congestive HF, and the mechanism is likely that the decline in myocardial function is related to apoptosis of cardiac myocytes that occurs apparently at random in the myocardium. Expand
Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
TLDR
This chapter summarizes the identified mechanisms that may play a role in anthracycline-induced cardiotoxicity and the types of cardiomyopathies that have been described in survivors treated with doxorubicin and the current recommendations for monitoring survivor for the development of cardiologistopathies. Expand
Role of Myocardial Strain Imaging in Chemotherapy Related Cardiotoxicity
TLDR
A review elaborating the role of myocardial strain imaging in chemotherapy related cardiotoxicity is presented, with an increasing emphasis on earlier and more accurate prediction of cardiot toxicity using imaging modalities besides evaluation of LVEF. Expand
Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology
TLDR
Evidence-based information is provided on the cardiotoxicity risk in cancer patients clinically diagnosed with COVID-19 who are receiving potentially cardiotoxic anti-cancer agents. Expand
Bortezomib Plus Melphalan-Induced Cardiomyopathy Presenting as Sinus Tachycardia and Systolic Heart Failure
TLDR
A case of a 70-year-old female with no known significant cardiac history presenting with partially reversible cardiomyopathy with initial presentation only being as sinus tachycardia is presented. Expand
Cardiotoxicity in HER2-positive breast cancer patients
TLDR
The aim of the current review aims to provide an overview of currently available data on the clinical spectrum of HER2-targeted agents and anthracyclines, as well as their pathogenic pathways involved in cardiotoxicity. Expand
An approach to chemotherapy-associated toxicity.
TLDR
An overview of commonly used chemotherapeutic drugs, indications for use, their adverse effects by organ system, and the management of commonly encountered toxicities is provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 70 REFERENCES
Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis
TLDR
Prophylaxis would be much more efficient if a biochemical marker of myocardiocyte damage could be reliably used to stop further chemotherapy at the correct time before irreversible progressive ‘macroscopic’ damage becomes evident upon imaging. Expand
Anticancer therapy induced cardiotoxicity: review of the literature
TLDR
The diagnostic work-up, the cardiotoxic risk of anthracyclines and trastuzumab, and additionally, cardiotoxicity as a risk factor of a multimodal therapeutic approach in breast cancer patients is discussed in this study. Expand
Cancer Therapy-Associated Cardiotoxicity and Signaling in the Myocardium
TLDR
The role of endothelial-myocardial communication in maintaining phenotype and survival of adult cardiomyocytes has increasingly been recognized and has demonstrated the importance of the ErbB/neuregulin signaling system in the adult heart. Expand
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
TLDR
This randomized study investigated whether valsartan, a new class of angiotensin II receptor blocker (ARB), can inhibit acute cardiotoxicity after doxorubicin‐based chemotherapy. Expand
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
TLDR
The potential cardiovascular toxicities for a range of cancer chemotherapeutic and chemopreventive agents are summarized and the importance of evaluating cardiovascular risk when patients enter into trials is emphasized and the need to develop guidelines that include collateral effects on the cardiovascular system is emphasized. Expand
Doxorubicin-induced cardiomyopathy.
TLDR
The tumors most commonly responding to doxorubicin when it is given as a single agent or in combination with other antitumor agents include breast and esophageal carcinomas; osteosarcoma, Kaposi's sarcoma and soft-tissue sarcomas; and Hodgkin's and non-Hodgkin's lymphomas. Expand
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of such toxicity depends on many factorsExpand
Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
TLDR
Assessing an individual's risk for anthracycline injury may be improved by having some measure of endogenous activity of this and other myocardial protective signals, and up-regulation of cardiac neuregulin signaling may be one strategy to limitMyocardial anthRacyclines injury. Expand
Role of biomarkers in cardioncology
TLDR
The role of troponin I in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing left ventricular ejection fraction reduction and late cardiac events represent an effective tool for the prevention of this complication. Expand
Cardioprotective interventions for cancer patients receiving anthracyclines.
TLDR
It is concluded that if the risk of cardiac damage is expected to be high, it might be justified to use dexrazoxane in patients with cancer treated with anthracyclines, however, for each individual patient clinicians should weigh the cardioprotective effect of dexraz oxane against the possible risk of a lower response rate. Expand
...
1
2
3
4
5
...